Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 7:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dysmenorrhea (Disorder) Clear all
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

NCT03986944
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
107
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jun 10, 2026, 7:55 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

NCT03213457
View directory record Official record
Conditions
Endometriosis
Interventions
Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
188
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Jun 10, 2026, 7:55 AM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Jun 10, 2026, 7:55 AM EDT
Withdrawn Phase 4 Interventional

Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis

NCT03325868
View directory record Official record
Conditions
Adenomyosis, Heavy Uterine Bleeding, Dysmenorrhea
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 51 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jun 10, 2026, 7:55 AM EDT
Completed Phase 4 Interventional Results available

Ulipristal for Endometriosis-related Pelvic Pain

NCT02213081
View directory record Official record
Conditions
Endometriosis
Interventions
Ulipristal
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Jun 10, 2026, 7:55 AM EDT
Not listed Not applicable Interventional

Iyengar Yoga Therapy for Dysmenorrhea and Endometriosis

NCT03784976
View directory record Official record
Conditions
Secondary Dysmenorrhea, Dysmenorrhea, Dysmenorrhea Secondary, Polycystic Ovary Syndrome, Endometriosis, Fibroid, Menstrual Pain, Menstrual Disorder, Menstrual Discomfort
Interventions
Iyengar Yoga Therapy
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
12 Years to 65 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Jun 10, 2026, 7:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

NCT03992846
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Chiefland, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jun 10, 2026, 7:55 AM EDT
Not yet recruiting Not applicable Interventional

Impact of Seed Cycling on Menstrual Regularity, Dysmenorrhea, and Premenstrual Symptoms

NCT07052500
View directory record Official record
Conditions
Menstruation Disorders, Menstrual Cramps, Menstruation
Interventions
Seed Cycling
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jun 10, 2026, 7:55 AM EDT
Terminated Phase 2 Interventional Results available

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

NCT01116440
View directory record Official record
Conditions
Pelvic Pain Associated With Refractory Endometriosis
Interventions
BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jun 10, 2026, 7:55 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

NCT00318500
View directory record Official record
Conditions
Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
49
States / cities
Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Jun 10, 2026, 7:55 AM EDT
Completed Phase 1 Interventional

Vaginal Bromocriptine for Treatment of Adenomyosis

NCT01821001
View directory record Official record
Conditions
Adenomyosis
Interventions
Vaginal Bromocriptine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jun 10, 2026, 7:55 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

NCT03343067
View directory record Official record
Conditions
Endometriosis
Interventions
elagolix, estradiol/norethindrone acetate (E2/NETA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jun 10, 2026, 7:55 AM EDT
Completed Phase 3 Interventional

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03204318
View directory record Official record
Conditions
Endometriosis Related Pain
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Jun 10, 2026, 7:55 AM EDT